Clinical Trial Update: Immune Response to the Consumption of Lactobacillus GG and FOS in Patients With Recurrent Herpes Labialis [NA]

View source ↗

Summary

A clinical trial evaluating immune responses to Lactobacillus GG and Fructooligosaccharides in patients with recurrent herpes simplex labialis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Labialis

Drugs mentioned

• Fructooligosaccharides (FOS) (Fructooligosaccharides)
• Lactobacillus GG (Lactobacillus rhamnosus GG) (Lactobacillus rhamnosus GG)

Snippet

Sponsor: Sprim Advanced Life Sciences | Conditions: Herpes Labialis | NA | Status: COMPLETED